GLP-1 receptor agonists (semaglutide, tirzepatide)

What it is

GLP-1 receptor agonists mimic a gut hormone. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are prescription-only in the US, EU and UK for type 2 diabetes and weight management. "Ozempic hair" became a mainstream search term in 2024-2026.

How it works

No direct follicle toxicity has been shown. The US labels say hair loss "was associated with weight reduction". The leading explanation is that rapid weight loss, calorie restriction and low protein, iron or zinc intake push many follicles early from growth into rest, causing diffuse shedding roughly 2-4 months later (see telogen effluvium). A 2026 review proposes fat-cell signalling to follicles as a link; that is a hypothesis, not a finding. Gupta 2026

What the studies show

• Wegovy label: hair loss in 3.3% on 2.4 mg weekly (4% of women, 0.9% of men) vs 1% on placebo, and 5.8% on 7.2 mg (8.4% of women). Wegovy label
• Zepbound label: about 5%, 4% and 5% at 5, 10 and 15 mg vs 1% on placebo; 7.1% of women vs 0.5% of men on drug. No one stopped treatment because of hair loss. Zepbound label
• A meta-analysis of 4,114 GLP-1 users (7 RCTs, 2 non-randomized) found a pooled hair-loss risk ratio of 3.25 (95% CI 1.44-7.36) versus placebo. Cheng 2026
• A systematic review of 24 studies found semaglutide and tirzepatide had the highest rates, women were disproportionately affected, and the semaglutide effect looked dose-dependent. Gupta 2026
• A large matched database cohort found higher odds of non-scarring alopecia and telogen effluvium with semaglutide and tirzepatide, but not of alopecia areata, and people with hair loss had lost more weight. Katragadda 2026
• Safety-database reports name GLP-1 drugs as the most-reported class for hair loss, but with no formal signal against a comparator class. Nakhla 2025

Caveats: trial "hair loss" is a self-reported adverse-event term, database studies are open to confounding, and media attention inflates reports. We found no long-term recovery follow-up.

How it's used in studies

Hair data come from weight-loss doses: semaglutide 2.4 mg weekly (7.2 mg in newer trials) and tirzepatide 5, 10 or 15 mg weekly. These are not hair treatments.

Side effects and safety

Hair effect: diffuse, non-scarring shedding appearing months after weight loss begins, more common in women; telogen effluvium in general usually recovers once the trigger settles. Other effects are dominated by stomach upset, and there is a boxed warning for thyroid C-cell tumours (from animal data). Do not stop a prescribed drug over hair worries without talking to the prescriber.

Bottom line

The signal is real, but absolute risk is a few percent and the best-supported cause is weight loss itself. Adequate protein and micronutrients are sensible, and heavy shedding is worth a check of ferritin, vitamin D and thyroid; see iron and ferritin. Patchy loss or a widening part is a different problem. Discuss with a doctor.

Fun facts

• On the Wegovy label women reported hair loss about 4 times as often as men (4% vs 0.9%); on Zepbound the gap was 7.1% vs 0.5%.
• Hair loss is one of the few common side effects the labels tie directly to the amount of weight lost.